|
Market Closed -
Nasdaq
16:00:00 2026-10-22 EDT
|
5-day change | 1st Jan Change | ||
| 39.42 USD | +0.48% |
|
+7.44% | +77.09% |
Company Valuation: LB Pharmaceuticals Inc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Market Cap 1 | 563.2 | 1,272 | - | - |
| Change | - | 125.81% | - | - |
| Enterprise Value (EV) 1 | 313 | 892.4 | 792.5 | 814.7 |
| Change | - | 185.11% | -11.2% | 2.8% |
| P/E | -7.11x | -6.9x | -7.47x | -7.15x |
| PBR | - | 2.99x | 3.09x | 3.44x |
| PEG | 0.1x | -0.1x | 0.98x | -1.6x |
| Capitalization / Revenue | - | - | - | 584x |
| EV / Revenue | - | - | - | 374x |
| EV / EBITDA | - | -5x | -3.85x | -3.79x |
| EV / EBIT | -10.3x | -4.78x | -3.85x | -3.13x |
| EV / FCF | -8.88x | -5.87x | -5.35x | -4.71x |
| FCF Yield | -11.3% | -17% | -18.7% | -21.2% |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -3.13 | -5.709 | -5.274 | -5.51 |
| Distribution rate | - | - | - | - |
| Net sales 1 | - | - | - | 2.178 |
| EBITDA 1 | - | -178.3 | -205.7 | -215 |
| EBIT 1 | -30.4 | -186.6 | -206 | -259.9 |
| Net income 1 | -25.2 | -178.2 | -201.1 | -234 |
| Net Debt 1 | -250.2 | -379.3 | -479.2 | -457 |
| Reference price 2 | 22.26 | 39.42 | 39.42 | 39.42 |
| Nbr of stocks (in thousands) | 25,299 | 32,259 | - | - |
| Announcement Date | 3/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.9x | - | -5x | - | 1.27B | |
| 18.38x | 6.48x | 12.88x | 1.62% | 63.29B | |
| 30.22x | 7.94x | 26.49x | 0.05% | 54.89B | |
| 36.58x | 6.5x | 19.41x | 0.88% | 53.28B | |
| 35.46x | 3.44x | 14.83x | -.--% | 45.81B | |
| 50.32x | 5.82x | 31.95x | -.--% | 43.46B | |
| -19.48x | 188.5x | -20.74x | -.--% | 40.23B | |
| 29.02x | 8.23x | 21.28x | 0.37% | 33.45B | |
| 27.38x | 5.77x | 14.95x | -.--% | 23.7B | |
| 32.79x | 5.99x | 20.16x | -.--% | 23.76B | |
| Average | 23.38x | 26.52x | 13.62x | 0.32% | 38.31B | |
| Weighted average by Cap. | 26.59x | 25.51x | 15.86x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- LBRX Stock
- Valuation LB Pharmaceuticals Inc
Select your edition
All financial news and data tailored to specific country editions
